

February 6, 2020

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sir,

Sub: Outcome of Board Meeting held on February 6, 2020.

The Board of Directors of the Company at its meeting held today, February 6, 2020, has inter alia, transacted the following businesses:

1. Approved the Un-audited Financial Results of the Company for the third Quarter and nine months period ended December 31, 2019 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. We enclose herewith the said Un-audited Financial Results along with the Limited Review Reports of the Statutory Auditors of the Company.
2. Approved a Second Interim Dividend @ 175% i.e Rs.1.75 (Rupee one and paise seventy five) per equity share of Re.1/- each on the equity share capital of the Company for the Financial Year 2019-20. The Company has fixed **February 18, 2020** as the **Record Date** for the purpose of payment of Second Interim Dividend and the same will be paid on or before **March 2, 2020**.

We enclose a copy of the Press Release on Un-audited Financial Results of the Company for the third quarter and nine months period ended December 31, 2019.

The Board meeting commenced at 3.00 p.m and concluded at 6.00 p.m.

Yours faithfully,

For **AUROBINDO PHARMA LIMITED**


B. Adi Reddy
Company Secretary

Enclosures: as above.



AUROBINDO PHARMA LIMITED

(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitriviham, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370; Fax: +91 40 23747340; Email: info@aurobindo.com

(Rs. In lakhs)

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2019

Particulars	Quarter ended			Nine months ended		Year ended
	31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from operations						
(a) Net sales/ income from operations	325,810	314,512	316,050	940,025	874,250	1,193,870
(b) Other operating income	8,757	7,654	8,760	24,591	23,481	31,919
Total revenue from operations	334,567	322,166	324,810	964,616	897,731	1,225,789
2 Other income						
(a) Foreign exchange gain (net)	2,110	-	5,180	4,148	-	-
(b) Others	1,688	3,364	8,507	5,592	9,207	10,960
Total other income	3,798	3,364	13,687	9,740	9,207	10,960
Total income (1+2)	338,365	325,530	338,497	974,356	906,938	1,236,749
3 Expenses						
(a) Cost of materials consumed	175,323	158,616	170,414	495,479	474,710	645,530
(b) Purchases of stock-in-trade	111	134	371	483	1,367	1,425
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	(6,490)	3,801	(2,243)	(10,261)	(15,290)	(28,980)
(d) Employee benefits expense	38,491	37,406	34,986	113,653	100,095	136,277
(e) Finance costs	2,131	2,486	4,141	7,812	9,608	13,092
(f) Foreign exchange loss (net)	-	436	-	-	2,110	1,032
(g) Depreciation and amortisation expense	11,855	11,793	10,910	35,163	30,370	41,303
(h) Other expenses	62,014	58,652	61,450	181,546	169,354	230,608
Total expenses	283,435	273,324	280,029	823,875	772,324	1,040,287
4 Profit before tax (1+2-3)	54,930	52,206	58,468	150,481	134,614	196,462
5 Tax expense						
Current tax	11,887	10,865	12,877	30,969	29,496	42,661
Tax credit - Minimum Alternate Tax (MAT)	-	-	(1,828)	-	(5,691)	(4,805)
Deferred tax	1,136	1,528	1,068	4,742	3,851	5,633
Total tax expense	13,023	12,393	12,117	35,711	27,656	43,489
6 Profit for the period/year (4-5)	41,907	39,813	46,351	114,770	106,958	152,973
7 Other Comprehensive income						
Items that will not to be reclassified subsequently to profit or loss:						
(a) Re-measurement of defined benefit liability	(357)	(680)	(49)	(1,092)	(148)	(217)
(b) Income-tax relating to items that will not be reclassified subsequently to profit or loss	125	238	17	382	52	76
8 Total Comprehensive income for the period/year (6+7)	41,675	39,371	46,319	114,060	106,862	152,832
9 Paid-up equity share capital (face value Re. 1 per share)	5,859	5,859	5,859	5,859	5,859	5,859
10 Other equity						1,129,203
11 Earnings per equity share (face value Re. 1 per share)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
(a) Basic (in Rs.)	7.15	6.80	7.91	19.59	18.25	26.11
(b) Diluted (in Rs.)	7.15	6.80	7.91	19.59	18.25	26.11

NOTES:

- The financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- The above standalone financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 6 February 2020. The statutory auditors have carried out limited review of the above results for the quarter and nine months ended 31 December 2019. An unmodified report has been issued by them thereon.
- Effective 1 April 2019, the Company adopted Ind AS 116, on all lease contracts existing on 1 April 2019 using the modified retrospective method with Right-of-use assets recognized at an amount equal to the lease liabilities in the balance sheet. Accordingly, comparatives for the year ended 31 March 2019 have not been retrospectively adjusted. On transition, the adoption of the standard resulted in recognition of Right-of-use assets (ROU) of Rs. 3,787 lakhs (includes reclassification of finance lease assets of Rs. 1,368 lakhs as at 31 March 2019) and lease liabilities of Rs. 2,419 lakhs. The adoption of the standard did not have any material impact to the financial results.
- The Company operates in only one segment viz., 'Pharmaceutical Products'.
- Sales of standalone include exports of Rs.277,421 lakhs for the current quarter (31 December 2018: Rs.263,033 lakhs).
- The Government of India, on 20 September 2019, vide the Taxation Laws (Amendment) Ordinance 2019, the Ordinance inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income tax at reduced rates as per the provisions/conditions defined in the said section. The Company has evaluated the above Ordinance and based on its evaluation currently the management proposed to continue with the old tax rates.
- The joint petition seeking sanction of the Hon'ble National Company Law Tribunal, Hyderabad Bench (NCLT) for the Scheme of Amalgamation of APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited, Silicon Life Sciences Private Limited and APL Healthcare Limited (all wholly owned subsidiary companies) with the Company has been admitted and is scheduled for hearing on 28 February 2020. Pending the disposal of the petition by NCLT, no adjustment has been made to the results for the period/year reported.
- The Board has approved second interim dividend @175% i.e., Re.1.75(Rupee One and Seventy five paise only) per equity share of Re.1 (Rupee One only) for the year 2019-20.
- Previous period figures have been regrouped/ rearranged wherever considered material and necessary to conform to the current period presentation.

Place: Hyderabad
Date: 6 February 2020


www.aurobindo.com



By Order of the Board

N. Govindarajan
Managing Director
DIN-00050482

FOR IDENTIFICATION ONLY

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City
Orwell, B Wing, 6th Floor, Unit-3
Sy. No. 83/1, Plot No. 2, Raidurg
Hyderabad-500081, India.

Telephone : +91 40 7182 2000
Fax : +91 40 7182 2399

Limited review report on unaudited standalone quarterly financial results and year-to-date results pursuant to the Regulation 33 of the Listing Regulations, 2015

To

Board of Directors of Aurobindo Pharma Limited

1. We have reviewed the accompanying Statement of unaudited standalone financial results of Aurobindo Pharma Limited ("the Company") for the quarter ended 31 December 2019 and year to date results for the period from 01 April 2019 to 31 December 2019 ("the Statement").
2. This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligation and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations'). Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with applicable accounting standards and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations including the manner in which it is to be disclosed, or that it contains any material misstatement.

For B S R & Associates LLP

Chartered Accountants

ICAI Firm Registration Number: 116231W/ W-100024



Sriram Mahalingam

Partner

Membership No.: 049642

UDIN: 20049642AAAAAL8722

Place: Hyderabad

Date: 6 February 2020

AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitrivihar, Ameerpet, Hyderabad - 500 038, India
Tel: +91 040 23736370; Fax: +91 40 23747340; Email: info@aubindo.com

(Rs. In lakhs)

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2019

Particulars	Quarter ended			Nine months ended		Year ended
	31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from operations						
(a) Net sales/ income from operations	579,944	551,827	517,526	1,667,455	1,402,394	1,922,592
(b) Other operating income	9,556	8,220	9,441	26,552	24,740	33,763
Total revenue from operations	589,500	560,047	526,967	1,694,007	1,427,134	1,956,355
2 Other income						
(a) Foreign exchange gain (net)	894	-	5,045	-	-	-
(b) Others	2,199	2,062	1,340	5,361	8,339	11,566
Total other income	3,093	2,062	6,385	5,361	8,339	11,566
Total income (1+2)	592,593	562,109	533,352	1,699,368	1,435,473	1,967,921
3 Expenses						
(a) Cost of materials consumed	201,115	181,547	192,256	568,700	545,370	744,499
(b) Purchases of stock-in-trade	55,310	51,570	55,184	159,887	143,099	194,320
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	75	3,715	(8,452)	(5,401)	(54,467)	(67,555)
(d) Employee benefits expense	79,780	77,719	64,980	235,485	187,141	258,487
(e) Finance costs	3,711	4,094	4,765	12,794	11,258	16,266
(f) Foreign exchange loss (net)	-	2,723	-	1,351	5,744	6,028
(g) Depreciation and amortisation expense	25,013	24,331	16,312	73,430	48,133	66,795
(h) Other expenses	132,416	128,751	114,361	383,147	316,831	431,410
Total expenses	497,420	474,450	439,406	1,429,393	1,203,109	1,650,250
4 Profit before share of (loss)/profit of joint ventures, exceptional items and tax (1+2-3)	95,173	87,659	93,946	269,975	232,364	317,671
5 Share of (loss)/profit of joint ventures, net of tax	(64)	7	257	414	322	270
6 Profit before exceptional items and tax (4+5)	95,109	87,666	94,203	270,389	232,686	317,941
7 Exceptional items (refer note 5)	1,292	1,276	2,504	3,838	5,188	8,806
8 Profit before tax (6-7)	93,817	86,390	91,699	266,551	227,498	309,135
9 Tax expense						
Current tax	21,796	21,695	21,365	63,016	52,209	71,207
Tax credit - Minimum Alternate Tax (MAT)	(39)	(237)	(2,551)	(276)	(6,758)	(5,100)
Deferred tax	1,529	979	1,664	5,759	4,123	6,578
Total tax expense	23,286	22,437	20,478	68,499	49,574	72,685
10 Profit for the period/year (8-9)	70,531	63,953	71,221	198,052	177,924	236,450
11 Other Comprehensive Income						
A) Items that will not be reclassified subsequently to profit or loss:						
i) Re-measurement of defined employee benefit liability	(357)	(686)	(49)	(1,098)	(138)	(261)
ii) Income-tax relating to items that will not be reclassified subsequently to profit or loss	125	239	14	383	49	107
B) Items that will be reclassified subsequently to profit or loss:						
i) Exchange differences on translating the financial statements of foreign operations	11,354	2,154	(17,309)	14,552	5,371	(266)
ii) Income-tax on items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
Total other comprehensive income for the period/year (net of tax)	11,122	1,707	(17,344)	13,837	5,282	(420)
12 Total Comprehensive income for the period/year (net of tax) (10+11)	81,653	65,660	53,877	211,889	183,206	236,030
Attributable to:						
Owners of the Parent Company	81,667	65,693	53,878	211,951	183,213	236,053
Non-controlling interest	(14)	(33)	(1)	(62)	(7)	(23)
Out of total comprehensive income above, Profit for the period/year attributable to:						
Owners of the Parent Company	70,545	63,986	71,222	198,114	177,931	236,473
Non-controlling interest	(14)	(33)	(1)	(62)	(7)	(23)
Other comprehensive income attributable to:						
Owners of the Parent Company	11,122	1,707	(17,309)	13,837	5,282	(420)
Non-controlling interest	-	-	-	-	-	-
13 Paid-up equity share capital (face value Re. 1 per share)	5,859	5,859	5,859	5,859	5,859	5,859
14 Other equity						
15 Earnings per equity share (face value Re. 1 per share)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
(a) Basic (in Rs.)	12.04	10.92	12.15	33.81	30.37	40.36
(b) Diluted (in Rs.)	12.04	10.92	12.15	33.81	30.37	40.36




NOTES:

- 1 The financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- 2 The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- 3 The above consolidated financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 6 February 2020. The statutory auditors have carried out limited review of the above results for the quarter and nine months ended 31 December 2019. An unmodified report has been issued by them thereon.
- 4 Effective 1 April 2019, the Group adopted Ind AS 116, on all lease contracts existing on 1 April 2019 using the modified retrospective method with Right-of-use assets recognized at an amount equal to the lease liabilities in the balance sheet. Accordingly, comparatives for the year ended 31 March 2019 have not been retrospectively adjusted. On transition, the adoption of the standard resulted in recognition of Right-of-use assets (ROU) of Rs. 51,977 lakhs (includes reclassification of finance lease assets of Rs. 11,594 lakhs as at 31 March 2019) and lease liabilities of Rs. 47,535 lakhs (includes reclassification of finance lease obligations of Rs. 7,152 lakhs as at 31 March 2019). The adoption of the standard did not have any material impact to the financial results.
- 5 Exceptional items for the current period/year represent acquisition related costs.
- 6 The Group operates in only one segment viz., 'Pharmaceutical Products'.
- 7 During the quarter, the following entities have been incorporated:
 - a) Aurobindo NV/SA, a wholly owned subsidiary of Agile Pharma B.V., w.e.f. 17 December 2019
 - b) LONGXIANG PHARMA TAIZHOU CO., LTD, a Joint venture under Helix Healthcare B.V. w.e.f 28 October 2019.
- 8 Aurobindo Pharma USA LLC a wholly owned subsidiary of Aurobindo Pharma USA Inc. was sold w.e.f.15 November 2019.
- 9 The Government of India, on 20 September 2019, vide the Taxation Laws (Amendment) Ordinance 2019, the Ordinance inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income tax at reduced rates as per the provisions/conditions defined in the said section. The Group has evaluated the above Ordinance and based on its evaluation currently the management proposed to continue with the old tax rates.
- 10 The joint petition seeking sanction of the Hon'ble National Company Law Tribunal, Hyderabad Bench (NCLT) for the Scheme of Amalgamation of APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited, Silicon Life Sciences Private Limited and APL Healthcare Limited (all wholly owned subsidiary companies) with the Parent Company has been admitted and is scheduled for hearing on 28 February 2020.
- 11 The Board has approved second interim dividend @175% i.e., Re.1.75(Rupee One and Seventy five paise only) per equity share of Re.1 (Rupee One only) for the year 2019-20.
- 12 Previous period figures have been regrouped/ rearranged wherever considered material and necessary to conform to the current period presentation.

Place: Hyderabad
Date :6 February 2020

www.aurobindo.com



By Order of the Board

N. Govindarajan
Managing Director
DIN-00050482

FOR IDENTIFICATION ONLY

B S R & Associates LLP

Chartered Accountants

Salarpuria Knowledge City
Orwell, B Wing, 6th Floor, Unit-3
Sy. No. 83/1, Plot No. 2, Raidurg
Hyderabad-500081, India.

Telephone : +91 40 7182 2000
Fax : +91 40 7182 2399

Limited review report on unaudited consolidated quarterly financial results and consolidated year-to-date results of Aurobindo Pharma Limited pursuant to the Regulation 33 of the Listing Regulations

To

The Board of Directors of Aurobindo Pharma Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Aurobindo Pharma Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net (loss)/ profit after tax and total comprehensive (loss)/ income of its joint ventures for the quarter ended 31 December 2019 and year to date results for the period from 01 April 2019 to 31 December 2019 ("the Statement"), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (SEBI) (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('Listing Regulations').
2. This Statement, which is the responsibility of the Parent's management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

S.No.	Name of the component	Country	Relationship
1	APL Research Centre Limited	India	Subsidiary
2	APL Healthcare Limited	India	Subsidiary
3	Auronext Pharma Private Limited	India	Subsidiary
4	Silicon Life Sciences Private Limited	India	Subsidiary
5	Auro Peptides Limited	India	Subsidiary
6	APL Pharma Thai Limited	Thailand	Subsidiary
7	All Pharma (Shanghai) Trading Company Limited	China	Subsidiary
8	Aurobindo Pharma USA Inc.	USA	Subsidiary
9	Natrol LLC	USA	Subsidiary

Limited review report on unaudited consolidated quarterly financial results and consolidated year-to-date results of Aurobindo Pharma Limited pursuant to the Regulation 33 of the Listing Regulations (continued)

S.No.	Name of the component	Country	Relationship
10	Aurolife Pharma LLC	USA	Subsidiary
11	Auro Health LLC	USA	Subsidiary
12	Auromedics Pharma LLC	USA	Subsidiary
13	Aurobindo Pharma USA LLC (Sold w.e.f 15 November 2019)	USA	Subsidiary
14	Auro AR LLC	USA	Subsidiary
15	Auro Vaccines LLC	USA	Subsidiary
16	Auro Logistics LLC	USA	Subsidiary
17	Auro Packaging LLC	USA	Subsidiary
18	Aurobindo Pharma Produtos Farmaceuticos Limitada	Brazil	Subsidiary
19	Helix Healthcare B.V.	The Netherlands	Subsidiary
20	Aurogen South Africa (Pty) Ltd	South Africa	Subsidiary
21	Aurobindo Pharma (Pty) Limited	South Africa	Subsidiary
22	Novagen Pharma (Pty) Limited	South Africa	Joint venture
23	Auro Pharma Inc.	Canada	Subsidiary
24	Aurovida Farmaceutica SA DE CV	Mexico	Subsidiary
25	Aurobindo Pharma Japan K.K.	Japan	Subsidiary
26	Aurobindo Pharma Colombia S.A.S	Colombia	Subsidiary
27	Agile Pharma B.V.	The Netherlands	Subsidiary
28	Arrow Generiques SAS	France	Subsidiary
29	1980 Puren Pharma GmbH	Germany	Subsidiary
30	Puren Pharma GmbH & Co., KG	Germany	Subsidiary
31	Aurovitas Spain SA	Spain	Subsidiary
32	Aurobindo Pharma B.V.	The Netherlands	Subsidiary
33	Aurex B.V.	The Netherlands	Subsidiary
34	Aurobindo Pharma GmbH	Germany	Subsidiary
35	Laboratorios Aurobindo S.L.	Spain	Subsidiary
36	Aurobindo Pharma (Italia) S.r.l	Italy	Subsidiary
37	Aurobindo Pharma (Romania) S.r.l.	Romania	Subsidiary
38	Pharmacin B.V.	The Netherlands	Subsidiary
39	Aurobindo Pharma (Malta) Limited	Malta	Subsidiary
40	APL Swift Services (Malta) Limited	Malta	Subsidiary
41	Milpharm Limited	United Kingdom	Subsidiary
42	Aurovitas Pharma Polska	Poland	Subsidiary
43	Generis Farmaceutica S.A	Portugal	Subsidiary
44	Generis Phar, Unipessoal Lda.	Portugal	Subsidiary
45	Aurobindo Pharma Saudi Arabia Limited Company	Saudi Arabia	Subsidiary
46	Aurobindo Pharma Industria Farmaceutica Ltda	Brazil	Subsidiary
47	Hyacinths Pharma Private Limited	India	Subsidiary
48	Raidurgam Developers Limited	India	Joint venture
49	AuroZymes Limited	India	Subsidiary
50	Curepro Parenterals Limited	India	Subsidiary
51	Eugia Pharma Specialities Limited	India	Joint venture

62

Limited review report on unaudited consolidated quarterly financial results and consolidated year-to-date results of Aurobindo Pharma Limited pursuant to the Regulation 33 of the Listing Regulations (continued)

S.No.	Name of the component	Country	Relationship
52	Tergene Biotech Private Limited	India	Joint venture
53	Auro Pharma India Private Limited	India	Subsidiary
54	Aurovitas Pharma Ceska republika s.r.o	Czech Republic	Subsidiary
55	Aurovitas Pharma (Taizhou) Ltd	China	Subsidiary
56	Acrotech Biopharma LLC	USA	Subsidiary
57	Purple Bellflower (Pty) Ltd	South Africa	Joint Venture
58	Auroscience (Pty) Ltd	Australia	Subsidiary
59	Auro Science LLC	USA	Subsidiary
60	Apotex Nederland BV, NL	The Netherlands	Subsidiary
61	APOTEX ESPANA SL	Spain	Subsidiary
62	Aurovitas spol s.r.o (Formerly known as APOTEX CR spol.s.r.o)	Czech Republic	Subsidiary
63	Apotex SA/NV	Belgium	Subsidiary
64	Apotex Polska Sp.z.o.o	Poland	Subsidiary
65	Apotex Europe BV	The Netherlands	Subsidiary
66	Sameko Farma B.V.	The Netherlands	Subsidiary
67	Leidapharm B.V.	The Netherlands	Subsidiary
68	Marel B.V.	The Netherlands	Subsidiary
69	Pharma Dossier B.V.	The Netherlands	Subsidiary
70	Aurobindo NV/SA (w.e.f. 17 December 2019)	Belgium	Subsidiary
71	Aurobindo Pharma FZ LLC, Dubai	U.A.E.	Subsidiary
72	Curateq Biologics GmbH	Switzerland	Subsidiary
73	Luoxin Aurovitas Pharm (Chengdu) Co., Ltd.	China	Joint Venture
74	Longxiang Pharma Taizhou Co., Ltd (w.e.f. 28 October 2019)	China	Joint Venture

5. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditors referred to in paragraph 6 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of 20 subsidiaries included in the Statement, whose interim financial information reflect total revenues (including other income) of Rs. 377,956 lakhs and of Rs 1,070,216 lakhs, total net profit after tax of Rs. 28,883 lakhs and Rs. 80,044 lakhs and total comprehensive income of Rs. 28,822 lakhs and Rs. 79,732 lakhs for the quarter ended 31 December 2019 and for the period from 01 April 2019 to 31 December 2019, respectively, as considered in the unaudited consolidated financial results. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the management and our conclusion in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the report of other auditors and the procedures performed by us as stated in paragraph 3 above.



Limited review report on unaudited consolidated quarterly financial results and consolidated year-to-date results of Aurobindo Pharma Limited pursuant to the Regulation 33 of the Listing Regulations (continued)

Certain of these subsidiaries are located outside India whose financial results and other financial information have been prepared in accordance with accounting principles generally accepted in their respective countries and which have been reviewed by other auditors under generally accepted auditing standards applicable in their respective countries. The Parent's Management has converted the interim financial information of such subsidiaries located outside India from accounting principles generally accepted in their respective countries to accounting principles generally accepted in India. We have reviewed these conversion adjustments, if any made by the Parent's Management. Our conclusion in so far on the Statement as it relates to the balances and affairs of such subsidiaries located outside India is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matter.

7. The Statement includes the interim financial information of 47 subsidiaries which have not been reviewed, whose interim financial information reflect total revenue (including other income) of Rs. 112,648 lakhs and Rs. 323,579 lakhs, total net (loss)/ profit after tax of Rs. (1,091) lakhs and Rs. 9,725 lakhs and total comprehensive (loss)/ income Rs. (1,091) lakhs and Rs. 9,725 lakhs for the quarter ended 31 December 2019 and for the period from 01 April 2019 to 31 December 2019, respectively, as considered in the Statement. The Statement also includes the Group's share of net profit after tax of Rs. 41 lakhs and Rs. 270 lakhs and total comprehensive income of Rs. 41 lakhs and Rs. 270 lakhs for the quarter ended 31 December 2019 and for the period from 01 April 2019 to 31 December 2019, respectively, as considered in the unaudited consolidated financial results, in respect of 7 joint ventures, based on their interim financial information which have not been reviewed. According to the information and explanations given to us by the management, these interim financial information are not material to the Group.

Our conclusion on the Statement is not modified in respect of the above matter.

For **B S R & Associates LLP**

Chartered Accountants

ICAI Firm Registration Number: 116231W/ W-100024

Sriram Mahalingam

Partner

Membership No.: 049642

UDIN: 20049642AAAAAK6771

Place: Hyderabad

Date: 6 February 2020

NEWS RELEASE

6th February 2020, Hyderabad, India

Aurobindo Pharma Ltd Q3 FY19-20 Financial Results
Consolidated Financial Results – Q3FY19-20

Amount in INR Cr	Q3 FY19-20	Q3 FY18-19	% Chg	Q2 FY19-20	% Chg
Revenue from Operations	5,895.0	5,269.7	11.9	5,600.5	5.3
EBITDA before Forex and Other income	1,208.0	1,086.4	11.2	1,167.5	3.5
EBITDA %	20.5%	20.6%		20.8%	
PBT before Forex and Exceptional Items	942.8	889.0	6.0	903.8	4.3
Net Profit after JV share, minority interest	705.3	712.2	-1.0	639.5	10.3

Key Highlights of Q3FY20 consolidated financials

- Revenue from Operations at INR 5,895.0 Cr, witnessed a strong growth of 11.9% over corresponding previous period
 - US formulations revenue of INR 2,969.4 Cr vs INR 2,433.2 Cr in Q3FY19, registering a healthy growth of 22.0% YoY
 - Europe formulations revenue at INR 1,476.3 Cr, an increase of 14.2% against Q3FY19
 - Growth Markets posted a growth of 1.6% YoY to INR 345.9 Cr
 - ARV formulations revenue at INR 313.4 Cr vs. INR 281.3 Cr, increased by 11.4% YoY
 - API revenue came in at INR 789.8 Cr vs. INR 921.7 Cr in the corresponding previous period
- EBITDA before Forex and Other income at INR 1,208.0 Cr, grew by 11.2% year-on-year; EBITDA margin for the quarter was at 20.5%
- Net Profit after JV share, minority interest at INR 705.3 Cr as against INR 712.2 Cr in the corresponding previous period.
- Basic & Diluted EPS is INR 12.04 per share.
- Research & Development (R&D) spend at INR 253.2 Cr, 4.3% of revenues
- Received final approval for 4 ANDAs and tentative approval for 1 ANDA from USFDA
- Board has approved second interim dividend @ 175% i.e., INR 1.75 per equity share of INR 1/- for the year FY19-20

Commenting on the Company's performance, Mr. N. Govindarajan, Managing Director of the company said: *"We continue to perform well across all our key geographies. We remain focused on strengthening our existing businesses and developing a differentiated and specialty driven product portfolio. We are committed to resolve all pending regulatory issues and continuously improve quality"*

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com



www.aurobindo.com

Operational Performance (Consolidated):

Amount in INR Cr	Q3 FY19-20	Q3 FY18-19	% Chg	Q2 FY19-20	% Chg
Formulations					
USA	2,969.4	2,433.2	22.0	2,835.5	4.7
Europe	1,476.3	1,292.8	14.2	1,401.3	5.4
Growth Markets	345.9	340.5	1.6	319.2	8.4
ARV	313.4	281.3	11.4	237.9	31.7
Total Formulations	5,104.9	4,347.8	17.4	4,793.8	6.5
Active Pharmaceuticals Ingredients (API)					
Betalactum	511.1	557.7	-8.4	517.5	-1.3
Non Betalactum	278.7	364.1	-23.5	288.3	-3.3
Total API	789.8	921.7	-14.3	805.8	-2.0
Consolidated Sales	5,894.7	5,269.6	11.9	5,599.7	5.3
Dossier Income	0.3	0.1		0.8	
Revenue from Operations	5,895.0	5,269.7	11.9	5,600.5	5.3

Consolidated Revenue breakup - Geography & segment wise

Q3FY20



Formulations

Formulation revenue for the quarter posted a growth of 17.4% YoY to INR 5,104.9 Cr and accounted for 86.6% of total revenues.

US Formulations

- US revenue for Q3FY20 witnessed a growth of 22.0% YoY to INR 2,969.4 Cr, accounting 50.4% of consolidated revenue. On constant currency basis, revenue grew by 23.5% YoY
- Filed 6 ANDAs with USFDA including 4 injectables in Q3FY20
- Received final approval for 4 ANDAs and tentative approval for 1 ANDA
- The company has launched 5 products during the quarter

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

- As on 31st Dec 2019, on a cumulative basis, the company filed 572 ANDAs with USFDA and received approval for 418 ANDAs including 27 tentative* approvals

**Tentative approvals include 8 ANDAs approved under PEPFAR.*

EU Formulations

- EU formulations revenue in Q3FY20 witnessed a growth of 14.2% YoY to INR 1,476.3 Cr, accounting 25.0% of consolidated revenue. In Euro terms, revenue grew by 19.1% YoY

ARV Formulations

- ARV business revenue for Q3FY20 was at INR 313.4 Cr Vs. INR 281.3 Cr in Q3FY19, increased by 11.4% and accounted for 5.3% of revenue

Growth Markets Formulations

- Revenue from Growth markets formulations in Q3FY20 up by 1.6% YoY to INR 345.9 Cr and accounted for 5.9% of revenue

API business

- API business clocked a sales of INR 789.8 Cr Vs. INR 921.7 Cr in the corresponding previous period

Global Regulatory Filings:

Filings	Q3 FY19-20	Cumulative Filings as on 31 st Dec 2019
ANDAs (including filings made from Aurobindo USA)	6	572
DMFs (including filings made from AuroNext and AuroPeptide)	-	253
Formulations Dossiers in other key advanced markets (incl. Multiple registrations into Europe, South Africa and Canada)	59	3,791
API DMF/COS filings in other key regulated markets (incl. Multiple registrations)	68	3,072

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

USFDA approvals received in Q3 FY19-20:

Final Approvals

1	Carbidopa (gLodosyn) tablets 25 mg	CNS
2	Guaifenesin (gMucinex) extended release tablets 600 mg & 1200 mg OTC	Respiratory
3	Naloxone Hydrochloride Inj 0.4 mg/ml (SDV)	Anti-dote
4	Naloxone Hydrochloride Inj 0.4 mg/ml (MDV)	Anti-dote

Tentative Approvals

1	Diclofenac Sodium Topical Solution (gPennsaid) 2% W/W	Anti-fungal
---	---	-------------

Earnings call details

The company will host earnings call at 8.30 AM IST on February 7th 2020, to discuss the performance and answer any questions from participants.

Participants can dial-in on the numbers below

Primary Number: +91 22 6280 1437 / +91 22 7115 8825

Local Access Number: +91 70456 71221 (Available all over India)

About Aurobindo Pharma Limited:

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP:IN) headquartered at Hyderabad, India, manufactures generic pharmaceuticals and active pharmaceutical ingredients. The company's manufacturing facilities are approved by several leading regulatory agencies like US FDA, UK MHRA, EU, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over 6 major therapeutic/product areas encompassing Antibiotics, Anti-Retroviral, CVS, CNS, Gastroenterological, Pain management and Anti-Allergic, supported by an outstanding R&D set-up. The Company is marketing these products globally in over 150 countries.

For further information, please contact:

Krishna Kiran

Investor Relations

Phone: 040-66725401 / 66725000

Mobile: +91 98486 67906

Email: ir@aurobindo.com

Disclaimer:

This press release contains statements that may constitute "forward looking statements" including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

AUROBINDO PHARMA LIMITED

(CIN : L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitriviham, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com

AUROBINDO PHARMA LIMITED
(CIN - L24239TG1986PLC015190)

Regd. Office: Plot No.2, Maitriviham, Ameerpet, Hyderabad - 500 038, India

Tel: +91 040 23736370; Fax: +91 40 23747340; Email: info@aurobindo.com

(Rs. In lakhs)

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31.12.2019						
Particulars	Quarter ended			Nine months ended		Year ended
	31.12.2019	30.09.2019	31.12.2018	31.12.2019	31.12.2018	31.03.2019
	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1 Revenue from operations						
(a) Net sales/ income from operations	5,79,944	5,51,827	5,17,526	16,67,455	14,02,394	19,22,592
(b) Other operating income	9,556	8,220	9,441	26,552	24,740	33,763
Total revenue from operations	5,89,500	5,60,047	5,26,967	16,94,007	14,27,134	19,56,355
2 Other income						
(a) Foreign exchange gain (net)	894	-	5,045	-	-	-
(b) Others	2,199	2,062	1,340	5,361	8,339	11,566
Total other income	3,093	2,062	6,385	5,361	8,339	11,566
Total income (1+2)	5,92,593	5,62,109	5,33,352	16,99,368	14,35,473	19,67,921
3 Expenses						
(a) Cost of materials consumed	2,01,115	1,81,547	1,92,256	5,68,700	5,45,370	7,44,499
(b) Purchases of stock-in-trade	55,310	51,570	55,184	1,59,887	1,43,099	1,94,320
(c) Changes in inventories of finished goods, stock-in-trade and work-in-progress	75	3,715	(8,452)	(5,401)	(54,467)	(67,555)
(d) Employee benefits expense	79,780	77,719	64,980	2,35,485	1,87,141	2,58,487
(e) Finance costs	3,711	4,094	4,765	12,794	11,258	16,266
(f) Foreign exchange loss (net)	-	2,723	-	1,351	5,744	6,028
(g) Depreciation and amortisation expense	25,013	24,331	16,312	73,430	48,133	66,795
(h) Other expenses	1,32,416	1,28,751	1,14,361	3,83,147	3,16,831	4,31,410
Total expenses	4,97,420	4,74,450	4,39,406	14,29,393	12,03,109	16,50,250
4 Profit before share of (loss)/profit of joint ventures, exceptional items and tax (1+2-3)	95,173	87,659	93,946	2,69,975	2,32,364	3,17,671
5 Share of (loss)/profit of joint ventures, net of tax	(64)	7	257	414	322	270
6 Profit before exceptional items and tax (4+5)	95,109	87,666	94,203	2,70,389	2,32,686	3,17,941
7 Exceptional items (refer note 5)	1,292	1,276	2,504	3,838	5,188	8,806
8 Profit before tax (6-7)	93,817	86,390	91,699	2,66,551	2,27,498	3,09,135
9 Tax expense						
Current tax	21,796	21,695	21,365	63,016	52,209	71,207
Tax credit - Minimum Alternate Tax (MAT)	(39)	(237)	(2,551)	(276)	(6,758)	(5,100)
Deferred tax	1,529	979	1,664	5,759	4,123	6,578
Total tax expense	23,286	22,437	20,478	68,499	49,574	72,685
10 Profit for the period/year (8-9)	70,531	63,953	71,221	1,98,052	1,77,924	2,36,450
11 Other Comprehensive Income						
A) Items that will not be reclassified subsequently to profit or loss:						
i) Re-measurement of defined employee benefit liability	(357)	(686)	(49)	(1,098)	(138)	(261)
ii) Income-tax relating to items that will not be reclassified subsequently to profit or loss	125	239	14	383	49	107
B) Items that will be reclassified subsequently to profit or loss:						
i) Exchange differences on translating the financial statements of foreign operations	11,354	2,154	(17,309)	14,552	5,371	(266)
ii) Income-tax on items that will be reclassified subsequently to profit or loss	-	-	-	-	-	-
Total other comprehensive income for the period/year (net of tax)	11,122	1,707	(17,344)	13,837	5,282	(420)
12 Total Comprehensive income for the period/year (net of tax) (10+11)	81,653	65,660	53,877	2,11,889	1,83,206	2,36,030
Attributable to:						
Owners of the Parent Company	81,667	65,693	53,878	2,11,951	1,83,213	2,36,053
Non-controlling interest	(14)	(33)	(1)	(62)	(7)	(23)
Out of total comprehensive income above, Profit for the period/year attributable to:						
Owners of the Parent Company	70,545	63,986	71,222	1,98,114	1,77,931	2,36,473
Non-controlling interest	(14)	(33)	(1)	(62)	(7)	(23)
Other comprehensive income attributable to:						
Owners of the Parent Company	11,122	1,707	(17,309)	13,837	5,282	(420)
Non-controlling interest	-	-	-	-	-	-
13 Paid-up equity share capital (face value Re. 1 per share)	5,859	5,859	5,859	5,859	5,859	5,859
14 Other equity						13,83,219
15 Earnings per equity share (face value Re. 1 per share)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
(a) Basic (in Rs.)	12.04	10.92	12.15	33.81	30.37	40.36
(b) Diluted (in Rs.)	12.04	10.92	12.15	33.81	30.37	40.36

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad - 500 084 T.S., INDIA Tel: +91 40 6672 5000 / 1200 Fax: +91 40 6707 4059

Regd. Off.: Plot No. 2, Maitriviham, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel: +91 40 2373 6370 Fax: +91 40 2374 7340, Email: info@aurobindo.com

www.aurobindo.com

NOTES:

- 1 The financial results of the Group have been prepared in accordance with the Indian Accounting Standards (Ind AS) prescribed under Section 133 of the Companies Act, 2013, read with the relevant rules issued thereunder.
- 2 The above consolidated financial results have been prepared in accordance with principles and procedures as set out in the Ind AS 110 on "Consolidated financial statements" and Ind AS 28 on "Investments in Associates and Joint ventures" notified under Section 133 of Companies Act, 2013 and Companies (Indian Accounting Standards) Rules, 2015, as amended.
- 3 The above consolidated financial results as reviewed by the audit committee have been approved by the Board of Directors at its meeting held on 6 February 2020. The statutory auditors have carried out limited review of the above results for the quarter and nine months ended 31 December 2019. An unmodified report has been issued by them thereon.
- 4 Effective 1 April 2019, the Group adopted Ind AS 116, on all lease contracts existing on 1 April 2019 using the modified retrospective method with Right-of-use assets recognized at an amount equal to the lease liabilities in the balance sheet. Accordingly, comparatives for the year ended 31 March 2019 have not been retrospectively adjusted. On transition, the adoption of the standard resulted in recognition of Right-of-use assets (ROU) of Rs. 51,977 lakhs (includes reclassification of finance lease assets of Rs. 11,594 lakhs as at 31 March 2019) and lease liabilities of Rs. 47,535 lakhs (includes reclassification of finance lease obligations of Rs. 7,152 lakhs as at 31 March 2019). The adoption of the standard did not have any material impact to the financial results.
- 5 Exceptional items for the current period/year represent acquisition related costs.
- 6 The Group operates in only one segment viz., 'Pharmaceutical Products'.
- 7 During the quarter, the following entities have been incorporated:
 - a) Aurobindo NV/SA, a wholly owned subsidiary of Agile Pharma B.V., w.e.f. 17 December 2019
 - b) LONGXIANG PHARMA TAIZHOU CO., LTD, a Joint venture under Helix Healthcare B.V. w.e.f 28 October 2019.
- 8 Aurobindo Pharma USA LLC a wholly owned subsidiary of Aurobindo Pharma USA Inc. was sold w.e.f.15 November 2019.
- 9 The Government of India, on 20 September 2019, vide the Taxation Laws (Amendment) Ordinance 2019, the Ordinance inserted a new Section 115BAA in the Income tax Act, 1961, which provides an option to the Company for paying income tax at reduced rates as per the provisions/conditions defined in the said section. The Group has evaluated the above Ordinance and based on its evaluation currently the management proposed to continue with the old tax rates.
- 10 The joint petition seeking sanction of the Hon'ble National Company Law Tribunal, Hyderabad Bench (NCLT) for the Scheme of Amalgamation of APL Research Centre Limited, Aurozymes Limited, Curepro Parenterals Limited, Hyacinths Pharma Private Limited, Silicon Life Sciences Private Limited and APL Healthcare Limited (all wholly owned subsidiary companies) with the Parent Company has been admitted and is scheduled for hearing on 28 February 2020.
- 11 The Board has approved second interim dividend @175% i.e., Re.1.75(Rupee One and Seventy five paise only) per equity share of Re.1 (Rupee One only) for the year 2019-20.
- 12 Previous period figures have been regrouped/ rearranged wherever considered material and necessary to conform to the current period presentation.

By Order of the Board

N. Govindarajan
Managing Director
DIN-00050482

Place: Hyderabad
Date :6 February 2020

www.aurobindo.com

AUROBINDO PHARMA LIMITED

(CIN :L24239TG1986PLC015190)

PAN No. AABCA7366H

Corp off.: The Water Mark Building, Plot No.11, Survey No.9, Hi-tech City, Kondapur, Hyderabad – 500 084 T.S., INDIA Tel : +91 40 6672 5000 / 1200 Fax : +91 40 6707 4059

Regd. Off. : Plot No. 2, Maitrivihar, Ameerpet, Hyderabad - 500 038 T.S., INDIA Tel : +91 40 2373 6370 Fax : +91 40 2374 7340, Email : info@aurobindo.com

www.aurobindo.com